Publication:
LBA10 Bemarituzumab (BEMA) plus chemotherapy for advanced or metastatic FGFR2b-overexpressing gastric or gastroesophageal junction cancer (G/GEJC): FORTITUDE-101 phase III study results

Loading...
Thumbnail Image

Institution Authors

Author

S.Y. Rha

R.A. Pazo Cid

A. Fernandez Montes

S. Qin

S.J. Klempner

A. Elme

H.M. Türk

C. Pozzo

A. Ranceva

J. Li

Advisor

Organizational Unit

Program

Language

Publisher

Elsevier BV

Journal Title

Journal ISSN

Volume Title

Abstract

Description

Source

OpenAire

Keywords

Keywords

Citation

Endorsement

Review

Supplemented By

Referenced By

0

Views

0

Downloads

View PlumX Details


Sustainable Development Goals